HUP0105391A2 - Immunogén lipószómakészítmények - Google Patents

Immunogén lipószómakészítmények

Info

Publication number
HUP0105391A2
HUP0105391A2 HU0105391A HUP0105391A HUP0105391A2 HU P0105391 A2 HUP0105391 A2 HU P0105391A2 HU 0105391 A HU0105391 A HU 0105391A HU P0105391 A HUP0105391 A HU P0105391A HU P0105391 A2 HUP0105391 A2 HU P0105391A2
Authority
HU
Hungary
Prior art keywords
preparation
liposome compositions
immunogenic liposome
immunogenic
antigenic
Prior art date
Application number
HU0105391A
Other languages
English (en)
Inventor
Jill Adler-Moore
Donald V. Cramer
William A. Ernst
Gary Fujii
L. Jeanne Perry
Original Assignee
Molecular Express, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Express, Inc. filed Critical Molecular Express, Inc.
Publication of HUP0105391A2 publication Critical patent/HUP0105391A2/hu
Publication of HUP0105391A3 publication Critical patent/HUP0105391A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány tárgya egy immunogén liposzómakészítmény, melyvezikulumképző lipideket valamint egy vagy több antigéndeterminánst ésegy hidrofób domént tartalmazó antigénszerkezetet tartalmaz. Akészítmény egy vagy több adjuvánst is tartalmazhat. A találmánytovábbá a fenti készítmény előállítási eljárásaira, valamint aliposzómakészítményt tartalmazó vakcinákra is vonatkozik. Ó
HU0105391A 1998-09-22 1999-09-22 Immunogenic liposome compositions HUP0105391A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10135198P 1998-09-22 1998-09-22
US40072399A 1999-09-21 1999-09-21

Publications (2)

Publication Number Publication Date
HUP0105391A2 true HUP0105391A2 (hu) 2002-05-29
HUP0105391A3 HUP0105391A3 (en) 2006-02-28

Family

ID=26798150

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105391A HUP0105391A3 (en) 1998-09-22 1999-09-22 Immunogenic liposome compositions

Country Status (31)

Country Link
EP (1) EP1115382B1 (hu)
JP (1) JP2002526436A (hu)
KR (1) KR100592825B1 (hu)
CN (1) CN1555254A (hu)
AP (1) AP2010A (hu)
AT (1) ATE468108T1 (hu)
AU (1) AU766772B2 (hu)
BG (1) BG65675B1 (hu)
BR (1) BR9914004A (hu)
CA (1) CA2344173C (hu)
CY (1) CY1110718T1 (hu)
CZ (1) CZ20011013A3 (hu)
DE (1) DE69942393D1 (hu)
DK (1) DK1115382T3 (hu)
EA (1) EA004797B1 (hu)
EE (1) EE200100168A (hu)
ES (1) ES2345695T3 (hu)
GE (1) GEP20053444B (hu)
HK (1) HK1039064A1 (hu)
HU (1) HUP0105391A3 (hu)
ID (1) ID29082A (hu)
IL (2) IL141675A0 (hu)
MX (1) MXPA01002973A (hu)
NO (1) NO330685B1 (hu)
NZ (2) NZ528055A (hu)
OA (1) OA11657A (hu)
PL (1) PL206260B1 (hu)
SK (1) SK287670B6 (hu)
UA (1) UA75327C2 (hu)
WO (1) WO2000016746A2 (hu)
ZA (1) ZA200101829B (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868651A4 (en) 2005-04-12 2010-10-06 Univ Duke METHOD FOR INDUCING ANTIBODIES THAT NEUTRALIZE THE HUMAN IMMUNODEFICIENCY VIRUS
EP2438926B1 (en) 2009-06-04 2016-03-23 M Bio Technology Inc. Vaccine for mycoplasma infection
EA034702B1 (ru) * 2011-04-26 2020-03-10 Молекулар Экспресс, Инк. Липосомные композиции
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
US20200054741A1 (en) * 2017-04-04 2020-02-20 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
KR20240033309A (ko) * 2022-09-05 2024-03-12 주식회사 차백신연구소 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
SE462375B (sv) * 1985-10-15 1990-06-18 Morgaardshammar Ab Centro Traadblock
DE3776966D1 (de) * 1986-05-20 1992-04-09 Wako Pure Chem Ind Ltd Funktionelle gruppen tragende liposome und verfahren zu deren herstellung.
FR2754543B1 (fr) * 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires

Also Published As

Publication number Publication date
BG105372A (en) 2001-10-31
CZ20011013A3 (cs) 2002-03-13
EA200100269A1 (ru) 2001-12-24
KR20010075261A (ko) 2001-08-09
OA11657A (en) 2004-12-08
SK3222001A3 (en) 2001-09-11
CA2344173A1 (en) 2000-03-30
KR100592825B1 (ko) 2006-06-23
WO2000016746A2 (en) 2000-03-30
CN1555254A (zh) 2004-12-15
WO2000016746A3 (en) 2000-11-23
CA2344173C (en) 2010-02-23
SK287670B6 (sk) 2011-05-06
NZ528055A (en) 2005-01-28
GEP20053444B (en) 2005-02-25
EP1115382A2 (en) 2001-07-18
DK1115382T3 (da) 2010-09-06
NO330685B1 (no) 2011-06-06
ZA200101829B (en) 2002-06-05
WO2000016746A9 (en) 2000-09-21
AP2001002096A0 (en) 2001-03-31
CY1110718T1 (el) 2015-06-10
ES2345695T3 (es) 2010-09-29
NO20011406D0 (no) 2001-03-20
PL348604A1 (en) 2002-06-03
DE69942393D1 (de) 2010-07-01
JP2002526436A (ja) 2002-08-20
AU766772B2 (en) 2003-10-23
MXPA01002973A (es) 2003-03-27
WO2000016746A8 (en) 2000-08-10
IL141675A (en) 2007-06-17
BR9914004A (pt) 2001-07-24
IL141675A0 (en) 2002-03-10
ATE468108T1 (de) 2010-06-15
ID29082A (id) 2001-07-26
NO20011406L (no) 2001-04-24
BG65675B1 (bg) 2009-06-30
AP2010A (en) 2009-06-29
NZ510442A (en) 2003-10-31
AU6035199A (en) 2000-04-10
HK1039064A1 (en) 2002-04-12
EP1115382B1 (en) 2010-05-19
PL206260B1 (pl) 2010-07-30
EE200100168A (et) 2002-06-17
EA004797B1 (ru) 2004-08-26
HUP0105391A3 (en) 2006-02-28
UA75327C2 (en) 2006-04-17

Similar Documents

Publication Publication Date Title
DE60039198D1 (de) Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
WO2002009746A8 (en) Vaccines comprising outer membrane vesciles from gram negative bacteria
HUP0101323A1 (hu) Vakcinakészítmények
HUP0101619A2 (hu) Adjuvánskészítmények
AU2002338832A1 (en) Vaccine
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
HUP0402067A2 (hu) Oltóanyagok
GB2322801A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
DE60136650D1 (de) Kosmetische zusammensetzung enthaltend vernetzte silikonelastomere
DK1034000T3 (da) Fremgangsmåde til fremstilling af vacciner til forebyggelse af de patogene virkninger relateret til en HIV-retrovirusinfektion
ATE419873T1 (de) Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs
EP1433464A3 (en) Hair cleansing composition
BR9506885A (pt) Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
WO2002096936A3 (en) Daptomycin and related analogs in crystalline form, their preparation and use
DE69714011D1 (de) Die erzeugung einer immunantwort gegen erwünschte determinanten
DK0973544T3 (da) Immuntolerant prothrombinkomplekspræparat
AU2001263245A1 (en) Preparation of hydroxyalkylcarbamates from six-membered cyclic carbonates
HUP0105391A2 (hu) Immunogén lipószómakészítmények
FI972054A (fi) Immunogeenisiä koostumuksia
HUP9701586A2 (hu) Javított inaktivált vakcinák
WO2001070265A3 (en) Lipopeptide adjuvants
ATE329615T1 (de) Borrelia burgdorferi bacterin
PL348550A1 (en) Ibdv mutant, vaccine containing it for protecting poultry against a disease caused by ibdv and method of protecting poultry against such disease
NO972605D0 (no) Ny fremgangsmåte for fremstilling av ranitidin
WO2002024147A3 (en) Avian pneumovirus vaccine

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished